Bivalent and quadrivalent HPV vaccines are available for women aged 29. Cervical cancer is the only clinically preventable malignancy. Since the HPV vaccine was launched, it has received a lot of attention from women, and HPV vaccination can effectively prevent the occurrence of cervical cancer. Clinically, 99% of cervical cancer is related to HPV infection. By injecting HPV attenuated vaccine, the body can be effectively stimulated to produce HPV antibodies to prevent cervical cancer. Currently, there are three types of HPV vaccines, namely bivalent HPV vaccine, quadrivalent HPV vaccine and nine-valent HPV vaccine. The bivalent HPV vaccine and quadrivalent HPV vaccine are suitable for women aged 9-45 years old, and the nine-valent HPV vaccine is suitable for women aged 16-25 years old, so women aged 29 years old can choose to receive the bivalent or quadrivalent HPV vaccine according to their own situation. Before receiving HPV vaccine, for women who have sexual intercourse, cervical cancer screening is recommended before receiving the vaccine. HPV vaccine is not a substitute for routine cervical cancer screening, and even after receiving HPV vaccine, cervical cancer screening should be performed regularly.